Original language | English (US) |
---|---|
Pages (from-to) | 100-101 |
Number of pages | 2 |
Journal | Neurology |
Volume | 76 |
Issue number | 1 |
DOIs |
|
State | Published - Jan 4 2011 |
ASJC Scopus subject areas
- Clinical Neurology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Neurology, Vol. 76, No. 1, 04.01.2011, p. 100-101.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Clinical/scientific notes
AU - Issa, Shirin S.
AU - Herskovitz, Steven
AU - Lipton, Richard B.
N1 - Funding Information: Disclosure: Dr. Issa reports no disclosures. Dr. Herskovitz receives royalties from the publication of Peripheral Neuropathies in Clinical Practice (Oxford University Press, 2010) and served as an expert witness on behalf of the U.S. Department of Health and Human Services, Vaccine Injury Compensation Program. Dr. Lipton serves/has served on scientific advisory boards for and received funding for travel from Bayer Schering Pharma, Merck Serono, GlaxoSmithKline, Endo Pharmaceuticals, Kowa Pharmaceuticals America, Inc., Allergan, Inc., Neuralieve Inc., and Ortho-McNeil-Janssen Pharmaceuticals, Inc.; has received funding for travel from the American Headache Society and the Diamond Headache Center; serves as Associate Editor of Cephalalgia and on the editorial boards of Neurology® and Headache; receives royalties from publishing Headache in Clinical Practice (Isis Medical Media, 2002), Headache in Primary Care (Isis Medical Media, 1999), Wolff's Headache (Oxford University Press, 2001, 2008), Managing Migraine: A Physician's Guide (BC Decker, 2008), and Managing Migraine: A Patient's Guide (BC Decker, 2008); has received speaker honoraria from the National Headache Foundation, the University of Oklahoma, the American Academy of Neurology, the Annenberg Foundation, Merck Serono, GlaxoSmithKline, and Coherex Medical; receives research support from the American Headache Society, National Headache Foundation, the Migraine Research Foundation, and the NIH (PO1AG03949 [Program Director, Project Leader], PO1AG027734 [Project Leader], RO1AG25119 [Co-I], K23AG030857 [Co-Mentor], K23NS05140901A1 [Co-Mentor], and K23NS47256 [Mentor]); and holds stock options in Minster Pharmaceuticals plc.
PY - 2011/1/4
Y1 - 2011/1/4
UR - http://www.scopus.com/inward/record.url?scp=78751631066&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=78751631066&partnerID=8YFLogxK
U2 - 10.1212/WNL.0b013e318203e91a
DO - 10.1212/WNL.0b013e318203e91a
M3 - Comment/debate
C2 - 21205699
AN - SCOPUS:78751631066
SN - 0028-3878
VL - 76
SP - 100
EP - 101
JO - Neurology
JF - Neurology
IS - 1
ER -